Searched for
SERUM INSTITUTE VACCINE
Cancer drug prices raised 50% as NPPA acts on shortage concernsIndia's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI fundingSerum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fres...
- Moderna and other groups get $60 million to develop Ebola vaccineCEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will supp...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
- Ebola at the gates: Why India must not let its guard downIndia is enhancing its surveillance protocols following an Ebola outbreak in the Democratic Republic of Congo and Uganda. One of two suspec...
- Ebola vaccine update: Russia claims a breakthrough; Oxford researchers, Serum Institute of India aim to begin trial in 3 monthsA new Ebola vaccine developed by Russian scientists shows promise against the current outbreak strain in the Democratic Republic of Congo. ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Oxford University strikes new malaria vaccine pact with Serum Institute of IndiaOxford University and Serum Institute of India are collaborating on a new malaria vaccine, R78C. This partnership aims to create a more eff...
- ET Awards: Cyrus Poonawalla reflects on SII’s mission of affordable vaccines and saving lives worldwideCyrus Poonawalla began Serum Institute of India in 1966 with a goal to make India self-reliant in healthcare. His vision was to provide aff...
- Poonawalla's clear shot at access for all via route socialCyrus S Poonawalla, chairman of Serum Institute of India, has created a legacy where business and social impact go hand in hand. His vaccin...
- Funding for innovations key for India to remain vaccine leader: Cyrus PoonawallaSpeaking to ET after receiving the Lifetime Achievement Award for 2025 as part of the ET Awards for Corporate Excellence, Cyrus Poonawalla,...
- Serum Institute signs deal with Aspen to sell vaccines in AfricaThe deal with Serum gives Aspen certainty on volumes, which will eventually more than cover an expected decline in revenues from its COVID ...
- Oxford University to get Poonawala vaccine research facility; to get GBP 50 million fundingSerum Life Sciences is wholly-owned by the Poonawalla family, owners of the Adar Poonawalla-led Serum Institute of India, and the proposed ...
- We won’t release Covishield for mass use until it's proven safe and immunogenic: SII"The incident with the Chennai volunteer though highly unfortunate was in no way induced by the vaccine and SII is sympathetic with the vol...
- Serum Institute rejects charges levelled by vaccine trial participant, will seek Rs 100 crore in damagesA 40-year-old man who took part in the 'Covidshield' vaccine trial in Chennai has alleged serious side effects, including a virtual neurolo...
- Serum Institute to launch Dengue Monoclonal in India in next two yearsScientific details of the vaccines remained unclear. However, the vaccine maker said it will begin registrations for the vaccine soon.
Load More
